Tigran Kostanyan, MD
Ophthalmology · Las Vegas, NVNPI 1164800827
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,297 of the $11,344 with a category attached, or 64.3%. 22 manufacturers reported payments, led by Ivantis, Inc at 43.4% of the total. Reporting peaked in 2021 at $5,881 and has fallen 70.1% since, to $1,757 in 2025.
Across 193 payments — averaging $58.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ivantis, Inc$5K
- AbbVie$1K
- Glaukos Corporation$1K
- Alcon$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$542
- Aerie Pharmaceuticals, Inc.$379
- plus $2K from 16 others
What the payments were for
- Consulting fees$3,50031%
- Travel & lodging$5004%
- Food & beverage$7,29764%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ivantis, Inc | 15 | $4,918 |
| AbbVie(2 entities) | 41 | $1,240 |
| Glaukos Corporation | 23 | $1,219 |
| Alcon | 25 | $1,142 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $542 |
| Aerie Pharmaceuticals, Inc. | 11 | $379 |
| Bausch & Lomb Americas Inc. | 11 | $306 |
| NEW World Medical,inc. | 2 | $240 |
| Nova Eye, Inc. | 2 | $230 |
| Tarsus Pharmaceuticals, Inc. | 10 | $182 |
| Amgen | 2 | $146 |
| Sun Pharmaceutical Industries Inc. | 6 | $116 |
| Novartis | 5 | $104 |
| Thea Pharma Inc. | 6 | $92 |
| ANI Pharmaceuticals, Inc. | 3 | $90 |
| Rxsight Inc | 1 | $83 |
| Sight Sciences, Inc. | 4 | $82 |
| Oyster Point Pharma, Inc. | 3 | $64 |
| Mallinckrodt Hospital Products Inc. | 2 | $52 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $41 |
| Dompe US, Inc. | 2 | $38 |
| Kala Pharmaceuticals, Inc. | 2 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$4,956
- DURYSTA$294
- iDoseTR$240
- VYZULTA$162
- Hydrus$147
- iStent inject W$144
- MIEBO$142
- XIIDRA$142
- enVista MX60 IOL$138
- LenSx$137
- TEPEZZA$129
- Kahook Dual Blade$126
- Streamline Surgical System$126
- Ahmed Glaucoma Valve$126
- Rocklatan$125
- Rhopressa$125
- XEN GLAUCOMA TREATMENT SYSTEM$124
- AcrySof IQ VIVITY IOL$109
How this compares
$11,344 in reported general payments places this provider in the 85th percentile of 121 ophthalmology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 194 | $109,401 |
| RestasisCyclosporine | 50 | $72,993 |
| RocklatanNetarsudil Mesylat/Latanoprost | 103 | $59,768 |
| RhopressaNetarsudil Mesylate | 99 | $53,938 |
| XiidraLifitegrast | 28 | $34,796 |
| VyzultaLatanoprostene Bunod | 46 | $20,692 |
| Alphagan PBrimonidine Tartrate | 41 | $19,217 |
| Prednisolone Acetate | 337 | $13,904 |
| Latanoprost | 946 | $9,480 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 476 | $8,361 |
| CombiganBrimonidine Tartrate/Timolol | 20 | $5,459 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 25 | $4,946 |
| Brimonidine Tartrate | 298 | $4,729 |
| Ketorolac Tromethamine | 218 | $4,488 |
| Travoprost | 33 | $4,298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $1,240 | $207,070305 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $379 | $113,706202 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $306 | $55,48874 claims |
| AlconSimbrinza | $1,142 | $4,94625 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $542 | $1,40813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 121 ophthalmology providers in Nevada.
Other ophthalmology in Las Vegas
- Eva LiangLas Vegas$496K
- Steven LeibowitzLas Vegas$147K
- Wonchon LinLas Vegas$43K
- Ravindranath ReddyLas Vegas$30K
- Emily SchorrLas Vegas$17K
- Frank LeeLas Vegas$12K
- Tushina ReddyLas Vegas$11K
- Kent WellishLas Vegas$10K
- Eissa HannaLas Vegas$10K
- Surjeet SinghLas Vegas$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.